Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Maltose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.54 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.46 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.46 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.59 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | AMY2A | P04746 | 3/20 | 0.53 |
| ▸ | TYR | P14679 | 2/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.49 |
| ▸ | GJA1 | P17302 | 1/20 | 0.48 |
| ▸ | GJB2 | P29033 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | IGF2R | P11717 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maltotriose SCHEMBL2377340 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL16786 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL373436 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL2229473 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Water SCHEMBL466158 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL19582547 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL373437 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL373528 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL7072560 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL1308532 | 1.00 | LGALS8 (0.59) | LGALS8LGALS3LGALS4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1709 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435138-B2 | Immunotoxins, formulations thereof and their use in medicine | PHILIKOS B.V. (NL) | 2025-10-07 | — | — | US | claimed |
| US-20250288624-A1 | LONG-TERM STABILIZATION, FORMULATION AND TABLETING OF LIVE MICROBIAL CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-09-18 | — | — | US | claimed |
| CN-119716089-A | CRM197 protein specificity neutralization detection method based on high expression | 浙江毓昌生物技术有限公司 | 2025-03-28 | — | — | CN | claimed |
| EP-4263801-B1 | CULTURE MEDIUM, METHOD OF MANUFACTURE AND METHOD OF BACTERIAL CULTURE | UNIV BOURGOGNE (FR) | 2025-02-05 | — | — | EP | claimed |
| WO-2024232927-A9 | LONG-TERM STABILIZATION, FORMULATION AND TABLETING OF LIVE MICROBIAL CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-01-23 | — | — | WO | claimed |
| WO-2024232927-A2 | LONG-TERM STABILIZATION, FORMULATION AND TABLETING OF LIVE MICROBIAL CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-11-14 | — | — | WO | claimed |
| US-20240150463-A1 | IMMUNOTOXINS, FORMULATIONS THEREOF AND THEIR USE IN MEDICINE | PHILIKOS B.V. (NL) | 2024-05-09 | — | — | US | claimed |
| CN-111629753-B | Immunotoxins, their formulations and their use in medicine | 菲利克斯有限公司 | 2024-05-03 | — | — | CN | claimed |
| US-20240034984-A1 | CULTURE MEDIUM, METHOD FOR PRODUCING SAME, AND BACTERIAL CULTURE METHOD | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2024-02-01 | — | — | US | claimed |
| CN-117264477-A | Stainless steel band with oxidation-resistant surface and preparation method thereof | 深圳市明鑫工业材料有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-1487966-A | A method for preparing an open porous polymer material and an open porous polymer material | 阿蒂姆普朗特有限公司 | 2004-04-07 | — | — | CN | claimed |
| EP-1353982-A1 | A METHOD FOR PREPARING AN OPEN POROUS POLYMER MATERIAL AND AN OPEN POROUS POLYMER MATERIAL | Artimplant AB (SE) | 2003-10-22 | — | — | EP | claimed |
| US-20030148931-A1 | Pharmaceutical compositions containing dds compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-07 | — | — | US | claimed |
| EP-1308171-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DDS COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-07 | — | — | EP | claimed |
| EP-0885016-B1 | THERMALLY STABILIZED CONTRAST AGENT | AMERSHAM HEALTH AS (NO) | 2003-04-16 | — | — | EP | claimed |
| WO-2002051920-A1 | A METHOD FOR PREPARING AN OPEN POROUS POLYMER MATERIAL AND AN OPEN POROUS POLYMER MATERIAL | ARTIMPLANT AB (SE) | 2002-07-04 | — | — | WO | claimed |
| EP-0804171-B1 | CHEWING TABLETS WITH AN EFFERVESCENT ACTION | GERGELY GERHARD (AT) | 2000-01-05 | — | — | EP | claimed |
| EP-0667245-A1 | Recording sheets containing alcohols and saccharides | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| EP-0252760-B1 | PROCESS TO PREPARE SOLID PRODUCTS CONTAINING OIL-SOLUBLE SUBSTANCE | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1993-03-03 | — | — | EP | claimed |
| US-4595418-A | Enzymatic saccharification of liquefied starch solution, concentration, seeding to cause crystallization, drying, aging | SANWA KOSAN KABUSHIKI KAISHA (JP) | 1986-06-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150463-A1 | IMMUNOTOXINS, FORMULATIONS THEREOF AND THEIR USE IN MEDICINE | CD74, SIGLEC7, CD2 | MEN1 4121/4885PTGS1 3508/4885PDE4A 3460/4885 |
| US-12435138-B2 | Immunotoxins, formulations thereof and their use in medicine | CD74, SIGLEC7, CD2 | MEN1 4121/4885PTGS1 3508/4885PDE4A 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.